## Oncology



**PHARMACY** toll-free phone 855.611.3399

Patient Information Prescriber + shipping information											
Patient Name: DOB:						Prescriber Name:					
Sex 🗆 Female 🚨 Male SS #:						NPI #:					
1° Language	:	Wt: □	l kg □ lbs Ht:	Address:							
Address:						Apt/Suite: City: State: Zip:					
Apt/Suite: City: State: Zip:						Contact:					
Phone:Alternate Phone:						Phone:Alternate Phone:					
Caregiver Name: Relation:											
Local Pharmacy: Phone:						Email Address:					
Insurance Plan: Plan ID#:						If shipping to prescriber: ☐ 1st Month ☐ Always ☐ Never					
Please fax a copy front and back of the insurance card(s).											
Clinical information (Please fax all pertinent clinical and lab information)											
Diagnosis/ICD-10 (C00-D49):											
Patient Type (if applicable):											
□ adult female NOT of reproductive potential □ child female NOT of reproductive potential											
□ adult female of reproductive potential □ child female of reproductive potential □ Date:											
BRAF mutation present (if applicable) ☐ V600E ☐ V600K Any prior treatment: ☐ No ☐ Yes (provide information below)											
	Prior	Therany	Reason for I	ation of Ther	tion of Therapy						
Prior Therapy Reason for Discontinua					Approximate start bate Approx				Killiato Ella Dato		
Comorbidities:											
Concomitant Medications:											
Allergies: NKDA Other:											
Prescriber information											
□ Cotellic™	Three 20 mg tablets (60 mg) for 21 days on, 7 days off Quantity: 63 tablets Refills:					□ Lonsurf® □ 15 mg/6.14 mg Quantity: Refills: □ 20 mg/8.19 mg Quantity: Refills:					
□ Zelboraf®	lboraf® Four 240 mg tablets (960 mg) every 12 hours Quantity: 240 tablets Refills:					Takemg (35 mg/m²/dose) twice daily on days 1 through 5 and 8 through 12 for each 28-day cycle within on hour of completion of morning and evening meals (round to the closest 5 mg).					
v'									29 day ayala		
□ Nisqaii	☐ Kisqali Starting dose: Three (3) 200 mg tablets with food 21 days on, 7 days off  Dose Reduction:200 mg tablet(s) with food for 21 days on, 7 days off					☐ Ninlaro® One 4 mg cap daily on days 1, 8 and 15 of a 28-day cycle Quantity: 3 capsules Refills:					
Quantity: 63 or tablets Refills:						□ Revlimid®* One 25 mg cap for 21 days on, 7 days off					
With letrozole	With letrozole One 2.5 mg tablets daily for 28 days Quantity 28 tablets Refills:					Qu	antity: 21 cap	sules Refills:	_		
						□ dexamethasone One 40 mg cap daily on days 1, 8, 15 and 22 of a 28-day cycle Quantity: 4 capsules Refills:					
☐ Ibrance®	☐ Ibrance® 100 mg capsule with food for 21 days on, 7 days off 125 mg capsule with food for 21 days on, 7 days off						☐ Zytiga® Four 250 mg tablets (1000 mg) once daily without food				
Quantity 21 capsule Refills:							antity: 120 tablets Refills:				
With letrozole One 2.5 mg tablets once daily  Quantity 28 tablets Refills:					With prednisone One 5 mg tablet twice daily with food Quantity: 60 tablets Refills:						
☐ Afinitor®		☐ Farydak®	☐ Iressa®	□ Revlimi	  d <sup>®</sup> **	☐ Tafinlar	®	☐ Thalomid®**		l Zelboraf®	
☐ Arimedex®		☐ Femara®	☐ Jadenu®	□ Rydapt		☐ Tagriss		☐ Tykerb®		2 Zolinza®	
⊒ Bosulif®		☐ Gleevec®	☐ Jakafi®	☐ Spryce		☐ Tamoxi	fen®	☐ Votrient®		<b>I</b> Zykadia™	
☐ Cometriq®		☐ Hycamtin®	■ Mekinist®	□ Sutent <sup>®</sup>	)	□ Tarceva	a <sup>®</sup>	☐ Xalkori®		<b>ì</b> Zydelig <sup>™</sup>	
☐ Erivedge®		Imbruvica™	■ Nexavar®	☐ Stivarg		Tasigna		☐ Xeloda®		J	
■ Exjade <sup>®*</sup>		☐ Inlyta®	☐ Pomalyst®**	☐ Sylatro	n®	☐ Temoda	ar®	☐ Xtandi®			
Strength(s):Directions:										· · · · · · · · · · · · · · · · · · ·	
Quantity: Refills: **Authorization											
Packaging: □ Normal □ Blister Pack											
		lled with generic (if avai	lable) unless prescribe	writes "DA	W" (dispense	e as written	:):				
	20 111	30.10.10 (ii avai			(2.0001100		· -				
Prescriber's Signature:  Date:											
Prescriber's Signature:											

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information